Eleanor Barnes

Q: What Schools Are Affiliated With Eleanor Barnes

Eleanor Barnes is affiliated with the following schools: University of Oxford, King's College London

Eleanor Barnes's AcademicInfluence.com Rankings

Eleanor Barnes

Philosophy

#7118

World Rank

#10280

Historical Rank

Logic

#4359

World Rank

#5642

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Eleanor Barnes's Degrees

PhD Medical Sciences King's College London

Why Is Eleanor Barnes Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Eleanor Barnes is a British physician at the John Radcliffe Hospital and a Professor of Hepatology and Experimental Medicine at the University of Oxford. She has studied hepatitis C and the development of the development of HCV vaccines. She is a Fellow of the Academy of Medical Sciences and serves as the lead for hepatology at the National Institute for Health Research Clinical Research Network.

(See a Problem?)

Eleanor Barnes's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (2020) (3297)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020) (1480)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes (2014) (1437)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020) (1079)
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 (2020) (884)
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 (2020) (884)
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) (850)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (2021) (812)
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (2021) (576)
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2022) (529)
Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) (427)
Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man (2012) (414)
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera (2021) (373)
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2020) (367)
MAIT cells are activated during human viral infections (2016) (366)
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease (2014) (343)
Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties (2010) (341)
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. (2004) (331)
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison (2020) (331)
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study (2020) (306)
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum (2022) (306)
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory (2014) (301)
Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species (2012) (271)
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. (2015) (239)
Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. (2012) (230)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2020) (228)
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel (2020) (218)
Type 1 Autoimmune Pancreatitis and IgG4-Related Sclerosing Cholangitis Is Associated With Extrapancreatic Organ Failure, Malignancy, and Mortality in a Prospective UK Cohort (2014) (207)
Genetic History of Hepatitis C Virus in East Asia (2008) (207)
COVID-19 and liver disease: mechanistic and clinical perspectives (2021) (206)
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry (2020) (204)
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine (2021) (191)
Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease (2016) (173)
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study (2020) (168)
The dynamics of T‐lymphocyte responses during combination therapy for chronic hepatitis C virus infection (2002) (163)
Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis (2014) (153)
Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort (2016) (149)
Hepatitis C virus drug resistance and immune‐driven adaptations: Relevance to new antiviral therapy (2009) (143)
Approaches, Progress, and Challenges to Hepatitis C Vaccine Development (2019) (139)
Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity (2017) (132)
Vaccination for hepatitis C virus: closing in on an evasive target (2011) (130)
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway (2022) (130)
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients (2020) (120)
Pervasive Influence of Hepatitis C Virus on the Phenotype of Antiviral CD8+ T Cells1 (2004) (117)
Interferon lambdas: the next cytokine storm (2011) (112)
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity (2021) (112)
Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease (2017) (106)
Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays (2020) (104)
Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus (2017) (102)
Genome-to-genome analysis highlights the impact of the human innate and adaptive immune systems on the hepatitis C virus (2017) (102)
Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes (2016) (96)
Immunoglobulin G4+ B‐cell receptor clones distinguish immunoglobulin G 4‐related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies (2016) (96)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial (2021) (93)
CD161int CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut (2015) (93)
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern (2021) (93)
Infection and hemostasis in decompensated cirrhosis: A prospective study using thrombelastography (1999) (91)
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses (2020) (88)
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. (2020) (87)
Determining risk factors for mortality in liver transplant patients with COVID-19 (2020) (86)
SARS-CoV-2 infection in patients with autoimmune hepatitis (2021) (84)
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2021) (80)
Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen–restricted immune pressure (2009) (75)
Prevention of infection caused by immunosuppressive drugs in gastroenterology (2013) (74)
Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state (2016) (73)
Interferon lambda 4 impacts the genetic diversity of hepatitis C virus (2019) (71)
Ever closer to a prophylactic vaccine for HCV (2013) (71)
Interferon lambda 4 impacts the genetic diversity of hepatitis C virus (2019) (71)
Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance (2011) (68)
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013 (2013) (64)
Impact of Alpha Interferon and Ribavirin on the Function of Maturing Dendritic Cells (2004) (64)
Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV) (2018) (62)
Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. (2003) (61)
Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype‐specific immunodominant CD8+ T‐cell epitope (2010) (61)
A Modified RNA-Seq Approach for Whole Genome Sequencing of RNA Viruses from Faecal and Blood Samples (2013) (60)
Ultra‐sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells (2004) (58)
MAIT cell activation augments adenovirus vector vaccine immunogenicity (2020) (58)
Hepatic iron is the major determinant of serum ferritin in NAFLD patients (2018) (58)
Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial (2021) (56)
Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy, and success (2003) (56)
ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens (2015) (56)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus (2020) (56)
T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors (2005) (55)
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors (2018) (54)
A Theoretical Framework for Quantitative Analysis of the Molecular Basis of Costimulation (2005) (51)
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study (2021) (51)
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study (2021) (51)
Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8+ T Cells by Persistent Viruses and Vaccines (2018) (50)
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2 (2020) (47)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. (2020) (47)
The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos (2010) (47)
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees (2022) (46)
LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study (2015) (45)
Phenotypic differences between IgG4+ and IgG1+ B cells point to distinct regulation of the IgG4 response. (2014) (45)
Applications and Limitations of Blood Eosinophilia for the Diagnosis of Acute Cellular Rejection in Liver Transplantation (2003) (45)
Immunity to hepatitis C virus: stunned but not defeated. (2002) (45)
Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. (2009) (45)
Adenoviral Vector Vaccination Induces a Conserved Program of CD8+ T Cell Memory Differentiation in Mouse and Man (2015) (44)
Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans (2016) (44)
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question (2021) (43)
Discovery of Novel Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients: A Preliminary Study (2012) (43)
Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern. (2021) (43)
HCV immunology–Death and the maiden T cell (2003) (41)
Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. (2010) (41)
Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease (2015) (41)
Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR (2016) (41)
Interobserver Variability in Histologic Evaluation of Liver Fibrosis Using Categorical and Quantitative Scores (2017) (41)
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus (2008) (41)
Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum (2022) (39)
T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study (2021) (37)
Cross‐reactivity of hepatitis C virus specific vaccine‐induced T cells at immunodominant epitopes (2014) (37)
Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 (2021) (36)
Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection (2016) (36)
SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus (2020) (36)
Characterization of the Specificity, Functionality, and Durability of Host T‐Cell Responses Against the Full‐Length Hepatitis E Virus (2016) (34)
Genome-wide Association Study for Alcohol-related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. (2020) (33)
Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection (2010) (32)
The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design (2015) (32)
CD161+CD4+ T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-γ (2012) (31)
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes (2018) (31)
Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (2020) (31)
Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. (2000) (31)
A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection (2019) (31)
Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection (2009) (31)
HCV genotypes--role in pathogenesis of disease and response to therapy. (2000) (30)
Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing (2015) (29)
Unique patterns of glycosylation in immunoglobulin subclass G4‐related disease and primary sclerosing cholangitis (2018) (28)
Clinical Manifestations and Long-term Outcomes of IgG4-Related Kidney and Retroperitoneal Involvement in a United Kingdom IgG4-Related Disease Cohort (2018) (28)
SARS‐CoV‐2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID‐19 Vaccination (2021) (28)
No evidence to support a role for Helicobacter pylori infection and plasminogen binding protein in autoimmune pancreatitis and IgG4-related disease in a UK cohort (2017) (28)
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 (2022) (27)
Antimicrobial prescribing by dentists in Wales, UK: findings of the first cycle of a clinical audit (2016) (27)
Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101 (2017) (27)
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses (2021) (27)
A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings (2020) (27)
Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA‐DR11 restricted epitopes (2004) (26)
Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood‐based fibrosis markers in patients with chronic liver disease (2020) (26)
Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine (2021) (25)
Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank (2016) (25)
Autophagy in T cells from aged donors is maintained by spermidine, and correlates with function and vaccine responses (2020) (25)
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group (2019) (25)
New Approaches for Biomarker Discovery: The Search for Liver Fibrosis Markers in Hepatitis C Patients (2011) (25)
T cell failure in hepatitis C virus infection. (2002) (25)
Thoracic involvement in IgG4-related disease in a UK-based patient cohort. (2017) (24)
Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study (2019) (24)
Effect of interferon-α on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study (2013) (24)
Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort (2018) (24)
An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes (2015) (23)
Treatment of chronic viral hepatitis C in children and adolescents: UK experience (2014) (22)
'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy. (2013) (22)
Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients (2021) (22)
Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus (2016) (22)
Phosphodiester content measured in human liver by in vivo 31P MR spectroscopy at 7 tesla (2017) (22)
Analysis of ‘driver’ and ‘passenger’ CD8+ T-cell responses against variable viruses (2004) (21)
Therapeutic vaccines in HBV: lessons from HCV (2015) (21)
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir (2019) (21)
CD8αα Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection (2013) (20)
Predictors of a favorable response to alpha interferon therapy for hepatitis C. (1999) (20)
Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C (2018) (20)
HCV genotype-3a T cell immunity: specificity, function and impact of therapy (2012) (20)
Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis (2020) (20)
The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV (2020) (20)
Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. (2019) (19)
Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection. (2021) (19)
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV (2022) (19)
The Application of Single-Cell RNA Sequencing in Vaccinology (2020) (19)
Protecting travellers from hepatitis A (2001) (18)
Divergent trajectories of antiviral memory after SARS-CoV-2 infection (2021) (18)
Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis (2019) (18)
Interferon-α induces negative biases in emotional processing in patients with hepatitis C virus infection: a preliminary study (2017) (18)
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia. (2020) (18)
Remission of Inflammatory Bowel Disease in Glucose-6-Phosphatase 3 Deficiency by Allogeneic Haematopoietic Stem Cell Transplantation (2019) (18)
Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection (2019) (18)
Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses (2020) (18)
Interpreting Viral Deep Sequencing Data with GLUE (2019) (18)
Acute hepatitis C: clinical aspects, diagnosis, and outcome of acute HCV infection. (2008) (18)
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing (2017) (17)
Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients (2021) (17)
The case for a universal hepatitis C vaccine to achieve hepatitis C elimination (2019) (17)
Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa (2019) (17)
Suppression of Hepatitis C Virus Replication is Maintained Long Term following Haart Therapy, in An Individual with HCV/HIV Co-Infection (2004) (17)
Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus (2019) (17)
Caring and curing: paediatric cancer services since 1960. (2005) (17)
Therapeutic vaccination for treatment of chronic hepatitis B (2021) (17)
Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. (1999) (16)
Cell-free DNA TAPS provides multimodal information for early cancer detection (2021) (16)
Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6 (2013) (16)
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway (2022) (15)
A 63-year-old man with a recurrent right-sided pleural effusion (2015) (15)
New roles for clinical pharmacists in general practice (2017) (15)
Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses. (2020) (14)
Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome (2018) (14)
Hepatitis E Virus Infection, Papua New Guinea, Fiji, and Kiribati, 2003–2005 (2014) (14)
MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans (2020) (14)
The surveillance and diagnosis of hepatocellular carcinoma. (2005) (14)
Characterizing Hepatitis C Virus–Specific CD4+ T Cells Following Viral‐Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure (2020) (13)
Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults (2020) (13)
Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans (2020) (12)
Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome (2020) (12)
Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity (2021) (12)
Targeted metagenomic sequencing enhances the identification of pathogens associated with acute infection (2019) (12)
Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. (2019) (11)
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus (2019) (11)
British Association for the Study of the Liver (1991) (11)
Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus (2020) (11)
The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization (2021) (11)
Infection of liver hepatocytes with SARS-CoV-2 (2022) (10)
National Institute for Health Research Health Informatics Collaborative: development of a pipeline to collate electronic clinical data for viral hepatitis research (2019) (10)
Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. (2020) (10)
Negative regulation of ACE2 by interferons in vivo and its genetic control (2020) (10)
Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa (2020) (10)
IgG4‐related sclerosing cholangitis (2017) (10)
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection (2021) (10)
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2021) (10)
NK cells limit therapeutic vaccine–induced CD8+T cell immunity in a PD-L1–dependent manner (2022) (9)
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy (2021) (9)
A comprehensive genomics solution for HIV surveillance and clinical monitoring in a global health setting (2018) (9)
Virological footprint of CD 4 + T-cell responses during chronic hepatitis C virus infection (2010) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Infection Frequency of Hepatitis C Virus and IL28B Haplotypes in Papua New Guinea, Fiji, and Kiribati (2013) (8)
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms (2020) (8)
Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study (2022) (8)
Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019 (2021) (8)
The science, economics, and effectiveness of combination therapy for hepatitis C (2000) (7)
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses (2022) (7)
Cancer prevalence in a metropolitan HIV clinic (2014) (7)
An exploration of factors associated with food protein‐induced enterocolitis syndrome: Birth, infant feeding and food triggers (2020) (7)
Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway (2020) (7)
What Are the Prospects for Controlling Hepatitis C? (2009) (7)
Immunology taught by rats (2017) (7)
Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a (2016) (6)
A pan‐genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice (2022) (6)
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75 (2022) (6)
A gene locus that controls expression of ACE2 in virus infection (2020) (6)
Hepatitis B virus resistance to tenofovir: fact or fiction? A synthesis of the evidence to date (2019) (6)
Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors. (2018) (6)
The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis (2021) (6)
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines (2013) (6)
1051 PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES (2009) (6)
Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analogues (2022) (6)
Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection (2021) (6)
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse (2018) (5)
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. (2021) (5)
Expansion of a Novel Subset of PD1+CXCR5-CD4+ T Peripheral Helper Cells in IgG4-Related Disease (2020) (5)
Emergence of a distinct HIV‐specific IL‐10‐producing CD8+ T‐cell subset with immunomodulatory functions during chronic HIV‐1 infection (2013) (5)
Apparent spontaneous clearance of chronic hepatitis C virus infection in a HIV co-infected patient with decompensated cirrhosis: a case report (2015) (5)
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus (2022) (5)
FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome (2021) (5)
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients (2019) (5)
Organ transplantation and discrimination. Patients with hepatitis B should not be given low priority. (2000) (5)
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure (2020) (4)
Immunoglobulin E, Eosinophils and Mast Cells in Atopic Individuals Provide Novel Insights in IGG4-Related Disease (2016) (4)
Activation of MAIT cells plays a critical role in viral vector vaccine immunogenicity (2019) (4)
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations (2020) (4)
Full-Length Characterization of Hepatitis C Virus Subtype 3a Reveals Novel Hypervariable Regions under Positive Selection during Acute Infection (2010) (4)
Cohort Profile: The National Institute for Health Research Health Informatics Collaborative: Hepatitis B Virus (NIHR HIC HBV) research dataset (2021) (4)
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses (2021) (4)
P74 CD161 expressing CD8+ T-cells; elusive players in viral hepatitis (2010) (4)
Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease. (2020) (4)
High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study (2021) (4)
Therapy of chronic hepatitis C virus infection in HIV co-infected people. (2004) (4)
O087 : IgG4+ B-cell receptor clones in peripheral blood distinguish IgG4-associated cholangitis/autoimmune pancreatitis from primary sclerosing cholangitis (2015) (4)
Human Leucocyte Antigen Associations in IGG4-Related Disease and Primary Sclerosing Cholangitis Stratified by IGG4 Levels, in a Multicenter UK Cohort (2016) (4)
The global distribution and prevalence of HCV genotypes (2014) (4)
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study (2021) (4)
Fxr as a new therapeutic target for COVID-19 (2021) (4)
SARS-CoV-2 in Pediatric Liver Transplant Recipients: The European Experience (2021) (4)
Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead. (2021) (3)
Characterising HCV specific CD4+ T-cells following viral-vectored vaccination, directly acting anti-virals and spontaneous viral cure (2020) (3)
Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection. (2020) (3)
Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir (2020) (3)
SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. (2022) (3)
Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis (2018) (3)
Correspondence on ‘The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease’ (2020) (3)
Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19 (2022) (3)
Natural and vaccine-induced antibody and cellular responses against emerging SARS-CoV-2 variants of concern (2021) (3)
mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals (2022) (3)
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam (2019) (3)
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam (2019) (3)
Screening and treatment for hepatitis C: a balanced perspective (2015) (3)
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C (2021) (3)
Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers (2022) (3)
PWE-295 Thrombin generation is normal in cirrhotics with acute variceal haemorrhage: results from a prospective study (2012) (3)
P355 GENE EXPRESSION ANALYSIS IDENTIFIES IMMUNE SIGNALING AND COMPLEMENT PATHWAYS IN IgG4-RELATED DISEASE (2014) (3)
Hepatitis B vaccine shortage: another symptom of chronic neglect? (2017) (3)
Public Health England HCV Resistance Group: overview and consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection. (2019) (3)
A single dose of anti-miR-122, RG-101, in CHC patients results in NK cell normalization with no effect on HCV-specific CD8+ T cell function (2017) (3)
65 A THERAPEUTIC VACCINE FOR HCV BASED ON NOVEL, RARE, ADENOVIRAL VECTORS (2011) (3)
Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers. (2021) (3)
Platelet and spleen volume criteria exclude more oesophageal varices needing treatment than Baveno VI criteria with 100% sensitivity (2018) (2)
Factors determining effectiveness of interferons in managing hepatitis C: new targets and new approaches (2010) (2)
The emerging mysteries of IgG4-related disease. (2014) (2)
Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus infection in South Africa (2018) (2)
Optimising delivery of therapeutic hepatitis B vaccines to induce resident memory T cells in the liver (2020) (2)
1183 IN VIVO ANTIGENIC TARGETS OF T CELLS INDUCED BY ADENOVIRAL VECTORED VACCINES IN PATIENTS WITH CHRONIC HCV INFECTION (2012) (2)
FRI-162-Prime-boost vaccination strategies using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice (2019) (2)
Sa1034 Microparticle Dependent Procoagulant Activity and Thrombin Generation is Increased in Patients With Cirrhosis Induced Coagulopathy (2012) (2)
Deep sequencing of hepatitis B virus (HBV) genomes using rolling circle amplification and Nanopore (2018) (2)
Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic (2011) (2)
Rolling circle amplification and nanopore-based deep sequencing of full-length HBV genomes (2018) (2)
Defining the key intrahepatic gene networks in HCV infection driven by sex (2022) (2)
Baseline characteristics of a large multi-site chronic HBV electronic health record-based cohort in the UK (2021) (2)
GS-05-MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans (2019) (2)
Impaired humoral and cellular response to primary COVID‐19 vaccination in patients less than 2 years after allogeneic bone marrow transplant (2022) (2)
Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa. (2020) (2)
A rare cause of an ileocaecal mass and lymphadenopathy (2011) (2)
THU-364-Liver cT1 predicts clinical outcomes in patients with chronic liver disease (2019) (2)
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2021) (2)
Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner (2021) (2)
Elevated serum and tissue levels of IgG4 in Primary Sclerosing Cholangitis are associated with a worse clinical outcome (2012) (1)
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease (2021) (1)
Helicobacter Pylori as a Microbial Antigen in IGG4-Related Disease (2016) (1)
1140 PHASE I TRIAL OF A HIGHLY IMMUNOGENIC AND DURABLE T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL, RARE, ADENOVIRAL VECTORS (2011) (1)
Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus (2018) (1)
In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control (2021) (1)
Treatment Outcomes and Drug-Related Adverse Effects in IGG4-Related Disease (2016) (1)
HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients (2018) (1)
Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination (2021) (1)
Increased IgG 4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG 4-related disease (2015) (1)
Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. (2021) (1)
1383 IGG4-PLASMA CELL INFILTRATE IN THE LIVER AND COLON OF CHILDREN WITH PRIMARY SCLEROSING CHOLANGITIS (2012) (1)
707 CD8AA T CELLS: A NOVEL LINEAGE ENRICHED IN THE LIVER IN CHRONIC HCV (2010) (1)
Correction: Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. (2019) (1)
Immune responses against the hepatitis C virus and the outcome of therapy (2008) (1)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus [version 2; peer review: 1 approved] (2020) (1)
The NIHR Health Informatics Collaborative: sharing electronic NHS clinical information to capture the hepatitis C treatment revolution (2017) (1)
942 ELEVATED SERUM IGG4 LEVELS IN MULTIPLE HEPATOBILIARY PATHOLOGIES (2012) (1)
Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a (2021) (1)
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study (2022) (1)
OC-069 Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic (2012) (1)
P228 IgG4-positive plasma cells in the colon of patients with ulcerative colitis are markers of endoscopic and histological disease activity (2013) (1)
Staging of non-alcoholic fatty liver disease through LC-MS/MS analysis of the urinary steroid metabolome (2018) (1)
540 Thrombin Generation is Normal in Cirrhotics Presenting With Acute Variceal Haemorrhage: Results From a Prospective Study (2012) (1)
P822 MULTIPARAMETRIC MAGNETIC RESONANCE SHOWS THAT OBESITY IS STRONGLY ASSOCIATED WITH HEPATIC STEATOSIS IN ADULTS AND CHILDREN AND CAN DIFFERENTIATE PATIENTS WITH NASH FROM NAFLD (2014) (1)
Reply to: "Multiparametric magnetic resonance imaging to predict clinical outcomes in patients with chronic liver disease: A cautionary note on a promising technique". (2017) (1)
Multi-parametric MRI can diagnose steatohepatitis and cirrhosis in patients with NAFLD (2014) (1)
937 ROTATIONAL THROMBOELASTOMETRY IN CIRRHOSIS: THE CLOT THICKENS! (2011) (1)
Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK (2023) (1)
Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? (2022) (1)
Characterisation of chronic hepatitis B virus infection in the UK and risk factors for hepatocellular carcinoma: a large electronic health record-based retrospective cohort study in the QResearch primary care database. (2022) (1)
Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study (2022) (1)
P048 Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: International registry data (2021) (1)
Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients using proteomics (2014) (1)
THORACIC INVOLVEMENT IN IGG4-RELATED DISEASE (2015) (1)
SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study (2022) (1)
T cell and humoral immune response to multiple SARS-CoV-2 variants including omicron (B1.1.529) after two doses of COVID-19 vaccine in patients with cirrhosis and liver diseases requiring immunosuppression: data from the EASL COVID-Hep network (2022) (1)
Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis (2022) (1)
Humoral and cellular immune responses to wild-type and omicron (B.1.1.529) SARS-CoV-2 variants following a fourth COVID-19 vaccination in liver transplant recipients and patients with autoimmune hepatitis (2022) (0)
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes (2022) (0)
Co-localisation of hepatitis C virus drug-resistant mutations and immune-driven adaptations for genotype 1 and 3: relevance to therapy outcome (2008) (0)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus [version 1; peer review: 1 approved with reservations] (2020) (0)
Chronic antigenic stimulation may predispose to the development of IgG4-related disease of bile ducts and pancreas (2013) (0)
CD161+gamma-delta T CELLS: DEFINING THEIR ROLE IN PATIENTS WITH AND WITHOUT CHRONIC HEPATITIS C (2011) (0)
Hepatitis C Virus (HCV) epidemiology, diagnosis and access to treatment in a UK cohort (2017) (0)
Therapeutic vaccines in HBV: lessons from HCV (2015) (0)
Case Report: Application of hepatitis B virus (HBV) deep sequencing to distinguish between acute and chronic infection (2021) (0)
Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination (2021) (0)
Implications of HCV genotype 3 specific immunity on cross-reactive vaccine design (2014) (0)
PTH-092 Discovery and quantitation of novel liver fibrosis biomarkers using proteomics (2015) (0)
Global variability in admission to intensive care units for patients with chronic liver disease and COVID-19: International registry data (2021) (0)
A highly immunogenic novel genetic vaccine against HCV (2012) (0)
Characterisation of the Specificity, Functionality and Durability of Host T-Cell Responses against the Full HEV Genome (2016) (0)
P207 Thoracic involvement in IgG4-related disease (2015) (0)
Host and viral factors that determine the clinical outcome of hepatitis C virus genotype 3a infection (2011) (0)
Cell mediated immune (CMI) response as a marker of hepatitis C virus infection in RIBA indeterminate blood donors (2003) (0)
An Ounce of HCV Prevention (2014) (0)
Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. (2020) (0)
Erratum : Correction: Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis (Clinical and translational gastroenterology (2019) 10 4 (e00020)) (2019) (0)
P50 Autoimmune hepatitis patients have comparable outcomes from SARS-CoV-2 infection to patients with liver disease of other aetiology despite immunosuppression: international registry data (2020) (0)
Dynamics of HBsAg clearance in a UK cohort of chronic HBV infection (2018) (0)
Analysis of HCV in South East Asia (2007) (0)
943 PROSPECTIVE MAGNETIC RESONANCE CHOLANGIOGRAM STUDY TO DEFINE THE PREVALENCE AND CHARACTERISTICS OF PRIMARY SCLEROSING CHOLANGITIS IN PATIENTS WITH ULCERATIVE COLITIS AND COLORECTAL DYSPLASIA (2012) (0)
IGG4-Related Disease is Associatied with CD4+ T Cell Activation and Regulation (2016) (0)
IgG4‐Related Liver and Biliary Disease (2020) (0)
Distinct immune and regulatory functions of IgG1+ and IgG4+ B cells in IgG4-related disease (2017) (0)
The Generation of an Immunogenic Second-Generation Conserved Segment HCV T Cell Vaccine to Target Multiple HCV Genotypes (2016) (0)
Sex effect on key intrahepatic gene networks in hepatitis C virus infection (2022) (0)
HCV T Cell Re-Vaccination Strategies using Simian Adeno and MVA Viral Vectors to Enhance and Maintain Anti-Viral Immunity (2016) (0)
Vaccines in clinical trials: infectious disease (2011) (0)
Full-length sequence analysis of HCV genotype-3A reveals novel regions of hypervariability (2007) (0)
OP13 CD8b low T cells are a prominent, functionally distinct population in chronic hepatitis B infection (2011) (0)
Genome-to-genome analysis reveals the impact of the human innate and 1 adaptive immune systems on the hepatitis C virus 2 (2016) (0)
Author response: Interferon lambda 4 impacts the genetic diversity of hepatitis C virus (2019) (0)
Stefano Colloca Induce Potent Cellular Immunity Across Multiple Species Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses (2011) (0)
1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE (2022) (0)
Leo Swadling memory vectors that primes , boosts , and sustains functional HCV-specific T cell A human vaccine strategy based on chimpanzee adenoviral and MVA (2014) (0)
The predictive value of MRI-based markers of liver disease on clinical outcomes in patients with cirrhosis (2020) (0)
PS-020-Spleen T1 and spleen diameter criteria can identify and exclude oesophageal varices accurately (2019) (0)
Responses to HCV in Man Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell (2011) (0)
Science Translational Medicine Podcast: 05 November 2014 (2014) (0)
British Association for the Study of the Liver Meeting (2000) (0)
Antibiotic administration changes the balance of effector and regulatory T-cells in the neonatal intestine (2011) (0)
OC-069 Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic (2012) (0)
Multiparametric magnetic resonance imaging can quantitatively assess fibroinflammatory response to direct acting antiviral treatment of hepatitis C virus. (2017) (0)
Liver function assessment using magnetic resonance imaging with gadoxetic acid administration (2018) (0)
MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING OF THE SPLEEN: AN ACCURATE AND NON-INVASIVE BIOMARKER OF PORTAL PRESSURE (2016) (0)
SAT-423-Spleen extracellular volume fraction and platelet count/spleen volume ratio are accurate non-invasive markers of portal hypertension (2019) (0)
Estimation of Liver Collagen Proportionate Area by Visual Inspection (2014) (0)
Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAAs (2020) (0)
Issue Cover (2020) (0)
IgG4-related disease (2019) (0)
University of Dundee Interferon lambda 4 impacts the genetic diversity of hepatitis C virus (2019) (0)
Mo1512 – Liver Ct1 Predicts Clinical Outcomes in Patients with Chronic Liver Disease (2019) (0)
Differential immune transcriptomic profiles between vaccinated and resolved HCV reinfected subjects (2022) (0)
PWE-294 Microparticle dependent procoagulant activity and thrombin generation is increased in patients with cirrhosis induced coagulopathy (2012) (0)
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms [version 1; peer review: 3 approved] (2021) (0)
OTH-1 SARS-CoV-2 Infection in patients with autoimmune hepatitis (2021) (0)
SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Research, 5, [181]. (2021) (0)
Immunology of hepatitis C virus (2004) (0)
Hepatitis C virus (HCV) cellular immune responses are induced during combination therapy but are not sustained. (2000) (0)
Enhanced thrombin generation in cirrhotics with coagulopathy and variceal bleeding (2011) (0)
HBV resistance following sequential antiviral prophylaxis for liver transplantation (2001) (0)
Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK (2022) (0)
Hepatitis C vaccines: how close are we to the promised land? (2020) (0)
The detection of rare populations of HCV specific CD8+ T-cells by the enrichment of HLA class I tetramers (2003) (0)
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses (2023) (0)
STOP-HCV - Stratified Medicine to Optimise Treatment for Hepatitis C Virus Infection (2017) (0)
Liver and Systemic Iron Loading Characterise Initial Disease Progression in Non-Alcoholic Fatty Liver Disease (2016) (0)
Accurate staging of non-alcoholic fatty liver disease through analysis of the urinary steroid metabolome (2017) (0)
Fusion of colour contrasted images for early detection of oesophageal squamous cell dysplasia from endoscopic videos in real time (2022) (0)
880 UPREGULATION OF REGULATORY T CELLS AND REDUCTION OF ANTI-VIRAL IMMUNE RESPONSES TO HEPATITIS C DURING VIRAL ERADICATION IN PATIENTS UNDERGOING ANTIVIRAL TREATMENT (2009) (0)
P821 NOVEL MRI TECHNIQUES FOR THE ASSESSMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (0)
Multi-parametric magnetic resonance can accurately assess NAFLD histological disease severity; comparison with transient elastography (2015) (0)
Co-Administration of Chimpanzee Adenoviral Vectors of Different Serotypes, for the Prevention of HCV and HIV Co-Infection (2016) (0)
Hepatic Lipid Composition is Associated with Liver Fibrosis Severity and Predicts Clinical Outcomes (2017) (0)
Multi-parametric MRI predicts clinical outcomes in unselected patients with liver disease - a non-invasive test that meets the AASLD criteria for clinical trials? (2014) (0)
Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial (2022) (0)
P.1.e.012 Effect of interferon-alfa on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study (2012) (0)
Variants APOE (rs429358) and TM6SF2 (rs187429064) confer risk to hepatocellular carcinoma (2021) (0)
P51 Liver transplantation does not significantly increase risk of mortality from SARS-CoV-2 infection: international registry data (2020) (0)
Prevalence of NASH cirrhosis in morbidly obese patients undergoing bariatric surgery (2015) (0)
A multi-disciplinary approach to igG4 related disease aids in diagnosis and management (2020) (0)
LBP-34-Effect of Resistance Associated Substitutions on Retreatment of HCV infected patients with prior failure to Direct Acting Antiviral Therapy (2019) (0)
A novel HBV vaccine using chimpanzee adenoviral vector, encoding HBV antigens with a shark invariant chain adjuvant, for use in HBV immunotherapy (2019) (0)
Highly immunogenic virally vectored T cell vaccine against HCV are able to induce specific CD4+T cell helper responses (2018) (0)
T2*magnetic resonance imaging is more sensitive than histology and serum ferritin for the assessment of iron overload in patients with NAFLD (2014) (0)
QUANTIFYING THE HETEROGENEITY OF LIVER INFLAMMATION AND FIBROSIS IN PRIMARY SCLEROSING CHOLANGITIS USING THE INTERQUARTILE RANGE OF IRON-CORRECTED T1 FROM MULTI-PARAMETRIC MRI. (2019) (0)
PTU-078 Liver Fibrosis Severity is Associated with Hepatic Lipid Composition as Assessed by Proton Magnetic Resonance Spectroscopy (2016) (0)
1276 WAIST CIRCUMFERENCE GREATER THAN 90CM IS A RISK FACTOR FOR HEPATIC STEATOSIS IN OTHERWISE HEALTHY ADULTS - A 3 TESLA MAGNETIC RESONANCE SPECTROSCOPY STUDY (2012) (0)
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms [version 1; peer review: 1 approved] (2021) (0)
Identification of novel resistance associated substitutions for sofosbuvir in HCV genotype 3a (2018) (0)
Vaccine-Induced HCV-Specific CD8+ T Cell Response Restricted by the Protective HLA Allele B*27: Broad Cross-Recognition of Evolving Viral Variants (2016) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Estimating the epidemiology of chronic Hepatitis B Virus (HBV) infection in the UK: what do we know and what are we missing? (2022) (0)
Cellular Immune Responses during High-Dose Interferon- (cid:1) Induction Therapy for Hepatitis C Virus Infection Induction (2009) (0)
Data from an electronic health informatics pipeline to describe clearance dynamics of Hepatitis B surface antigen (HBsAg) and e-Antigen (HBeAg) in chronic HBV infection (2018) (0)
OTU-020 Altered FC and FAB glycosylation status in patients with IGG4-related sclerosing cholangitis and autoimmune pancreatitis (2018) (0)
Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV) (2019) (0)
Sequencing Methods Developed for Hepatitis C Identifies a New Virus, Human Hepegivirus 1, in Patients with Advanced Cirrhosis (2016) (0)
Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID-19 patients as prognostic markers (2020) (0)
Pan-genotypic probe-based enrichment to improve efficiency of Hepatitis B virus sequencing (2023) (0)
Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. Viral (2021) (0)
Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort (2020) (0)
Development and validation of personalised risk prediction models for early detection and diagnosis of primary liver cancer among the English primary care population using the QResearch® database: research protocol and statistical analysis plan (2022) (0)
Excess mortality risk among hepatitis C patients after being “cured” in the interferon-free era: results from three population-based cohorts (2022) (0)
974 SEROPREVALENCE OF HEPATITIS E IN THE SOUTH PACIFIC ISLANDS (2013) (0)
Baseline risk factors for liver cancer development in a large multisite chronic HBV electronic health record-based cohort in the UK (2021) (0)
SPECIAL FOCUS y Vaccines in clinical trials: infectious disease (2011) (0)
Global prevalence and phylogenetic evolution of hepatitis B virus resistance associated mutations using published GenBank data (2019) (0)
Identifying Hepatocellular Carcinoma from imaging reports using natural language processing to facilitate data extraction from electronic patient records (2022) (0)
A novel chimpanzee adenoviral vectored HBV vaccine, encoding multiple HBV antigens with a shark invariant chain adjuvant, for use in HBV immunotherapy (2018) (0)
Polymorphisms in the genotype 3 hepatitis C virus polymerase protein modify the response to interferon and sofosbuvir. (2017) (0)
T-cell and dendritic cell function and the effects of combination therapy in hepatitis C virus infection (2004) (0)
P257 Real world experience of the new ACR-EULAR classification criteria for IgG4-related disease (2021) (0)
Author response: Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses (2020) (0)
Hepitopes: literature review and database of HLA Class I epitopes in Hepatitis B Virus (HBV) (2016) (0)
Variants APOE (rs429358) and TM6SF2 (rs187429064) modify the risk of hepatocellular carcinoma (2022) (0)
T Cell Functionality in Chronic Hepatitis C Patients Treated With the Anti-miR-122 RG-101 (2016) (0)
Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT (2021) (0)
Function, phenotype and development of human CD161+CD8 T cells (2012) (0)
COVID-19 and liver transplantation: the jury is still out – Authors' reply (2020) (0)
Phenotype of Antiviral CD 8 Pervasive Influence of Hepatitis C Virus on (2004) (0)
New proteomic approaches for biomarker discovery: The search for novel liver fibrosis markers in hepatitis C patients (2014) (0)
Genome-To-Genome Virus-Host Analysis Reveals HCV Genotype 3 Viral Polymorphisms Linked Viral Load and to Host HLA Class-I/II and IL28B Alleles (2016) (0)
Characterisation of resistance associated substitutions in direct acting antivirals treatment naive patients with genotype 3 hepatitis C virus (2017) (0)
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates (2022) (0)
Author response for "Divergent chemokine receptor expression and the consequence for human IgG4 B cell responses" (2020) (0)
STRATEGIC TREATMENT OPTIMIZATION FOR HCV (STOPHCV-1): AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF SHORT DURATION THERAPY FOR CHRONIC HEPATITIS C (2019) (0)
Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus (2023) (0)
Co-localisation of Hepatitis C virus drug-resistance mutations and immune-driven adaptations: relevance to therapy outcome (2009) (0)
Impairment of CD8 T cell memory in DAA treated HCV/HIV co-infected patients (2019) (0)
No change in hepatitis C virus-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients (2017) (0)
DOP20 Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium (2022) (0)
Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens (2023) (0)
HCV+ Subjects 29.08.17.xlsx (2017) (0)
85 IL28B GENETIC STATUS IN ASSOCIATION WITH HCV SPECIFIC T-CELL IMMUNITY (2011) (0)
P1241 A FULLY-AUTOMATED PIPELINE FOR SEQUENCING WHOLE VIRAL GENOMES WITHOUT VIRUS-SPECIFIC PCR AMPLIFICATION TO DETERMINE HCV RESISTANCE TO ANTIVIRAL THERAPY (2014) (0)
Prime-boost vaccination using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice (2019) (0)
CostimulationAnalysis of the Molecular Basis of A Theoretical Framework for Quantitative (2005) (0)
Steroid priming prior to lamivudine in patients with highly replicating chronic HBV infection and minimally elevated ALT. (2002) (0)
CD8sslow-a novel differentiation marker and a prominent population in chronic hepatitis B infection (2012) (0)
Hepatitis B virus surface gene mutations are often associated with lamivudine resistance mutations in the absence of treatment with hepatitis B immunoglobulin (HBIG) (2003) (0)
O5 High rates of mortality and acute-on-chronic liver failure with SARS-CoV-2 infection in patients with cirrhosis: international registry data (2020) (0)
EFFECT OF INTERFERON-α ON CORTICAL GLUTAMATE IN PATIENTS WITH HEPATITIS C : A PROTON MRS STUDY (2013) (0)
O161 CROSS-REACTIVITY OF HCV SPECIFIC, VACCINE INDUCED T CELLS, USING AN IN VITRO PRIMING MODEL (2014) (0)
[443] HIGH DOSE INTERFERON-ALPHA INDUCTION THERAPY IS ASSOCIATED WITH A PROFOUND LOSS OF IL-2 AND IFN-y SECRETING HCV SPECIFIC T-CELLS (2007) (0)
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms [version 1; peer review: awaiting peer review] (2020) (0)
Interferon lambda 4 impacts broadly on hepatitis C virus diversity (2018) (0)
O07 FXR antagonists as new agents for COVID19 (2021) (0)
A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes (2018) (0)
276 MULTIPLE NOVEL PEPTIDE EPITOPES IN HCV GENOTYPE-3A IDENTIFIED USING TWO PARALLEL APPROACHES (2011) (0)
Related articles (2013) (0)
COMBINED LIVER AND KIDNEY TRANSPLANTATION IN THE TREATMENT OF VITAMIN B12 RESISTANT METHYLMALONIC ACIDAEMIA. (1999) (0)
P92 CD161+ γ-δ T cells: defining their role in patients with and without chronic hepatitis C (2011) (0)
Novel functions, phenotype and homing of Human CD8aa cells (2010) (0)
PTU-100 The role of a multi-regional specialist multi-disciplinary meeting in diagnosis and management of igg4-related disease (2019) (0)
Intensive care unit (icu) escalation more likely among liver transplant (lt) recipients with sarscov-2 compared to patients with decompensated cirrhosis (2021) (0)
OP15 Discovery of new liver fibrosis markers in hepatitis C patients using proteomics (2011) (0)
Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin (2016) (0)
Hepatitis C Virus (HCV) diagnosis, epidemiology and access to treatment in a UK cohort (2017) (0)
Viremia Frequencies of a Novel Human Pegivirus Evaluation by using Bioinformatic Screening and PCR (2016) (0)

This paper list is powered by the following services:

Other Resources About Eleanor Barnes

en.wikipedia.org

What Schools Are Affiliated With Eleanor Barnes?

Eleanor Barnes is affiliated with the following schools:

Eleanor Barnes's Academic­Influence.com Rankings